Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
Amgen Will Invest $20 Million in Provention Equity
Amgen Will be Responsible for Clinical Trial Supply and Manufacturing
PR Newswire
THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018